Amid the threat of pharmaceutical tariffs from President Donald Trump, recent months have seen multibillion-dollar U.S.

Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem ...

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion (OPDP). | Sprout ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

Havas Media Network has set up an advertising marketplace to help companies reach patients who are cut off from healthcare by ...

With great power comes great responsibility, and Insulet, accordingly, is using its influence in the diabetes management ...

Despite an outcry from the biopharmaceutical industry, the U.K. government has kept the rebate rate under a national ...

Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with ...

Established five years ago as a first-of-its-kind manufacturer dedicated to broadening access to medicines and protecting ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...